FOSUNPHARMA(SH:600196) Qi Lu Wan Bao·2026-01-06 13:35Group 1 - The National Medical Products Administration (NMPA) announced that the Coenzyme Q10 injection produced by Jiangsu Wanbang Biopharmaceutical Group Co., Ltd. does not meet regulatory standards [1][3] - The non-compliance issues include characteristics, insoluble particles, visible foreign matter, and content measurement [3] - The regulatory authorities have ordered the company to suspend sales and usage of the affected product, recall it, and conduct an in-depth investigation into the reasons for non-compliance [3] Group 2 - Jiangsu Wanbang Biopharmaceutical Group Co., Ltd. is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (600196), which is part of the larger Fosun Pharmaceutical Group established in 1994 [3] - The company was renamed to Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. in 2024 and focuses on research and development, manufacturing, and market promotion in various therapeutic areas [4] - The company operates over 20 member enterprises and has established 8 production bases across China, with business operations in more than 40 countries and regions worldwide [4]